EGFR and head and neck squamous cell carcinoma: Our previous work demonstrated that small molecule EGFR inhibitors including erlotinib decreased VEGF mRNA expression, decreased secretion of VEGF protein, and blunted HIF-1α induction in response to hypoxia in SQ20B head and neck squamous cell carcinoma cells [20].